United States Epilepsy Market Research Report to 2032
ID: MRFR/HC/11381-US | 100 Pages | Author: MRFR Research Team| December 2023
Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
ID: MRFR/HC/11381-US | 100 Pages | Author: MRFR Research Team| December 2023
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
US Epilepsy Market Highlighted Trends & Dynamics
The global epilepsy market in the Americas is undergoing significant segmentation, with North America poised to emerge as the dominant force in this medical landscape. The growth trajectory in this region is primarily attributed to the increasing prevalence of epilepsy disorders, particularly among the geriatric population. According to a 2015 report from the Center for Disease Control and Prevention (CDC), 1.2% of the US population, equivalent to 3.4 million individuals, were diagnosed with epilepsy. Within this demographic, 3 million were adults, and 470,000 were children affected by this neurological condition.The rising incidences of road traffic injuries and birth-related injuries contribute substantially to the prevalence of epilepsy in North America. The Epilepsy Foundation of America reported that, in 2018, approximately 1.3 to 2.8 million people in the US were diagnosed with epilepsy. The increasing recognition of epilepsy cases can be attributed to advancements in scientific fields, such as genetics and molecular biology, and the utilization of biomarkers for disease identification. The commitment of policymakers to adopt precision medicine also plays a pivotal role in acknowledging and addressing epilepsy cases.
A Morbidity and Mortality Weekly Report from the CDC highlighted that there are more people living with epilepsy in the US than ever before. Collaborative efforts between organizations like the Epilepsy Foundation and the CDC are dedicated to helping individuals overcome the challenges associated with epilepsy. The financial burden of epilepsy-related expenses in the US alone was reported to be around USD 15.5 billion in 2016, according to the RSC Diagnostic Report. The increasing prevalence of epilepsy in the US contributes to the rising costs of treatment, further propelling the market in the region.
The situation in Latin America, particularly in Brazil, sheds light on the broader landscape of epilepsy prevalence. According to a 2016 report from the World Health Organization, the prevalence rate of epilepsy in Brazil was recorded at 7.8 per 1000 inhabitants, with an overall prevalence rate of active epilepsy at 5.6 per 1000 inhabitants. The findings indicate a crucial association between improved health conditions and education levels, influencing the lower prevalence of epilepsy in Brazil.
In conclusion, the epilepsy market in the Americas, particularly in North America, is witnessing substantial growth driven by the increasing prevalence of epilepsy disorders. The concerted efforts of organizations, advancements in medical research, and the commitment of policymakers to precision medicine are instrumental in recognizing and addressing epilepsy cases. The financial implications of epilepsy-related expenses underscore the significance of ongoing research, medical innovation, and collaborative initiatives to enhance the overall management and understanding of epilepsy in the Americas.
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
